Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-LASV Dose Finding Trial in Healthy Volunteers
NCT04055454Phase 1Completed
- Sponsor
- Themis Bioscience
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MV-LASV in Lassa fever (3 arms), sponsored by Themis Bioscience. Primary endpoint: Rate of solicited and unsolicited Adverse Events at 56 days. Started Sep 2019; status: completed.
02
Drugs
MV-LASV
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT04055454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055454.